PubRank

Kamila Wojas-Krawczyk

Author PubWeight™ 7.37‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer. Contemp Oncol (Pozn) 2012 0.89
2 Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients. Oncol Rep 2013 0.85
3 The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study. J Cancer Res Clin Oncol 2014 0.85
4 EGFR gene mutations in patients with adenosquamous lung carcinoma. Asia Pac J Clin Oncol 2014 0.84
5 The incidence of EGFR-activating mutations in bone metastases of lung adenocarcinoma. Pathol Oncol Res 2013 0.82
6 Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients. J Cancer Res Clin Oncol 2014 0.82
7 The application of real-time PCR technique to detect rare cell clones with primary T790M Substitution of EGFR gene in metastases of non-small cell lung cancer to central nervous system in chemotherapy naive patients. Pathol Oncol Res 2014 0.80
8 Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer--a pilot study. Folia Histochem Cytobiol 2012 0.78
9 [Evaluation of Th1/Th2 lymphocyte balance and lipopolysaccharide receptor expression in asthma patients]. Pneumonol Alergol Pol 2009 0.78
10 The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors. Chemotherapy 2012 0.76
11 Phenotype of dendritic cells generated in the presence of non-small cell lung cancer antigens - preliminary report. Folia Histochem Cytobiol 2008 0.75
12 Prognostic value of synaptophysin and chromogranin a expression in patients receiving palliative chemotherapy for advanced non-small-cell lung cancer. Respiration 2012 0.75
13 Methodological recommendations for the diagnostics of EGFR gene mutations and ALK gene rearrangement in the selection of non-small-cell lung cancer patients to molecularly targeted therapies. Pneumonol Alergol Pol 2014 0.75
14 Remission of advanced EGFR-positive lung adenocarcinoma after short and intermittent erlotinib therapy. Pol Arch Med Wewn 2015 0.75